On June 12, 2019, the Minister of Health tabled the final report, A Prescription for Canada: Achieving Pharmacare for All, from the Advisory Council on the Implementation of National Pharmacare (the Council) (see also: news release and backgrounder). The Council recommends that Canada implement universal, single-payer, public pharmacare by enacting new legislation, and proceeding in a stepwise approach to implementation. As reported previously, the 2019 Federal Budget announced funding for some of the steps, including the formation of an arms-length national drug agency.
The final report outlines a timeline for implementation. By January 1, 2022, the new agency would be responsible for the creation of a national formulary, listing essential medicines covering about half of all prescriptions and most major conditions. By 2027, this initial formulary would be expanded to a fully comprehensive formulary. Also by January 1, 2022, the report calls for the establishment of a strategy for expensive drugs for rare diseases.
The Council recommends the enactment of new legislation, separate and distinct from the Canada Health Act. The legislation would outline how governments will work together and share costs, list federal responsibilities and include steps for opting in by provincial and territorial governments.
In a statement, the Minister of Health stated that the government “will carefully review the Council’s final report and its recommendations” over the coming months. However, Parliament has adjourned until September 16, 2019, and implementation of the Council’s recommendations may depend on what happens in the federal election, which is scheduled for October 21, 2019.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada and the Competition Bureau commit to information sharing to combat false, misleading or deceptive health claims
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperat...Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More